Tumores colorrectales
Desarrollo y puesta en marcha de una estrategia de medicina personalizada en pacientes con cáncer colorectal.
Grupo consolidado en el manejo de pacientes con cáncer colorectal que reúne y coordina en un equipo multidisciplinar toda la investigación básica, clínica y traslacional realizada en la Clínica Universidad de Navarra y en el Centro para la Investigación Médica Aplicada (CIMA) en torno al desarrollo e innovación terapeutica en el cáncer de colon.
Aparicio, B, Silva, L, Ruiz, M, Llópiz, D, Repáraz, D, Theunissen, P, Tamayo, I, Egea, J, Igea, A, Smerdou, C, Peñas, M, Perpiñá, C, Matilla, A, Varela, M, Reig, M, de la Torre-alaez, M, Argemí, J, Sangro, B, Hervás-Stubbs, S, Sarobe, P
"Immunogenicity of neoantigens from hepatocellular carcinoma patients treated with a combined radioimmunotherapy".
OncoImmunology. 15(1): 2645280. 2026. [doi:10.1080/2162402X.2026.2645280]
Manji, GA, Chung, V, Oh, DY, Lacy, J, Lopez, CD, Ponz-Sarvisé, M, Macarulla, T, Thomas, R, George, B, Alistar, A, Siveke, JT, Xu, Y, Lau, J, Cha, E, Kim, KP, O'Reilly, EM
"Atezolizumab and motixafortide, cobimetinib or simlukafusp alfa in pretreated advanced pancreatic cancer: phase I/IIb MORPHEUS-PDAC umbrella study".
Oncologist. 31(4): oyag023. 2026. [doi:10.1093/oncolo/oyag023]
Ducreux, M, Hackert, T, Macarulla, T, Melisi, D, Ponz-Sarvisé, M, Prager, G, Ringl, H, Taieb, J, Vogel, A, Wasan, H, Thallinger, C, Zielinski, C
"Diagnosis and treatment of pancreatic cancer: an expert opinion from the 9th CECOG Pancreas Cancer Academy".
Memo-Mag. Eur. Med. Oncol.. . 2026. [doi:10.1007/s12254-026-01107-1]
Sanmamed, MF, de Andrea, CE, Ruiz-Guillamon, D, Rodriguez-Ruiz, ME, Ortego, I, Eguren-Santamaría, I, Benito, A, Lopez-Janeiro, A, Gomariz, JG, Villalba-Esparza, M, Molina, A, Krasko, A, Ponz-Sarvise, M, Lopez-Picazo, JM, Gomis, G, Molero-Glez, P, Alexandru, R, Pérez-Domínguez, P, Rodriguez, I, Sanchez-Gregorio, S, Perez-Gracia, JL, Melero, I
"Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab".
Clin. Cancer Res.. 32(6): 1036 - 1045. 2026. [doi:10.1158/1078-0432.CCR-25-2502]
Schram, AM, Park, JJ, Italiano, A, Kitano, S, Guo, Y, Li, J, Bedard, PL, van Marcke, C, Ko, R, Lunger, L, Klotz, DM, Hussain, J, Maier, D, Erzen, D, Planchard, D, Prenen, H, Clay, TD, Park, JO, Kim, HD, Hernando-Calvo, A, Maruki, Y, Ponz-Sarvise, M, Dumbrava, E
"Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumors".
Future Oncol.. 22(7): 795 - 803. 2026. [doi:10.1080/14796694.2026.2637740]
Yoo, C, Fabregat-Franco, C, Lin, CC, Qvortrup, C, Oh, D, Yau, T, Kim, HD, Castet, F, Sarvise, MP, Hsu, C, Rohrberg, KS, Lichtenegger, FS, Franjkovic, I, Kratochwil, NA, Bessa, J, Rossmann, E, Schwalie, PC, Rieder, N, Pöschinger, T, Sie, CG, Dettling, S, Schlenker, R, Jiang, TY, Dai, CQ, Yun, HY, Hall, E, Te-Ying, AY, Hoves, S, Cannarile, MA, Schiff, C, Sangro, B
"First-in-human phase 1 study of RO7119929, an oral TLR7 agonist prodrug, in patients with advanced primary or metastatic liver cancers".
J. Immunother. Cancer. 14(3): e012783. 2026. [doi:10.1136/jitc-2025-012783]
Ponz-Sarvisé, M, Rha, SY, Gomez-Roca, CA, Morán, LO, Gill, S, Tortora, G, Geva, R, Saada-Bouzid, E, Santoro, A, Kim, TW, Heudobler, D, Dutcus, CE, Okpara, CE, Ghori, R, Zhang, YW, Vajdi, A, Dettman, EJ, Jin, F, Groisberg, R, Shapira-Frommer, R
"Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study".
Cancer Res. Commun.. 6(3): 673 - 686. 2026. [doi:10.1158/2767-9764.CRC-26-0018]
García-Alfonso, P, Alcaide-Garcia, J, Aguilar, EA, Elez, E, Montes, AF, Escobar, IG, Grávalos, C, García, IM, Viladot, CM, Vivas, CS, Sastre, J, Tarazona, N, Jimenez-Fonseca, P
"Definition of lines of treatment in metastatic colorectal cancer: a Delphi consensus".
Clin. Transl. Oncol.. 28(2): 617 - 624. 2026. [doi:10.1007/s12094-025-03986-y]
Sehouli, J, Van Gorp, T, Braicu, E, Sen, S, Boni, V, Kristeleit, R, Garcia, IM, Ochsenreither, S, Richardson, DL, Spira, A, Starodub, A, Wolf, J, De Graaf, K, Hock, B, Fingerle-Rowson, G, Houvras, Y, Vasconcelos, I, Gonzalez-Martin, A
"NAPISTAR 1-01: A Phase 1 dose escalation study of TUB-040, a novel NaPi2b-targeting exatecan antibody-drug conjugate in patients with platinum-resistant high grade serous ovarian carcinoma".
Int. J. Gynecol. Cancer. 36(2): 103078. 2026. [doi:10.1016/j.ijgc.2025.103078]
Bunuales, M, Inoges, S, de Cerio, ALD, Hervas-Stubbs, S, Rodriguez, J, Gonzalez-Aparicio, M, Jauregui, P, Hernandez-Alcoceba, R
"Evaluation of methods to increase the expression of cytokine-induced killer cell chemoattractant cytokines in pancreatic cancer".
Gene Ther.. . 2026. [doi:10.1038/s41434-025-00590-1]
|